These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 2186820

  • 1. Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates.
    Munn DH, Garnick MB, Cheung NK.
    Blood; 1990 May 15; 75(10):2042-8. PubMed ID: 2186820
    [Abstract] [Full Text] [Related]

  • 2. Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
    Qi CF, Nieroda C, De Filippi R, Greiner JW, Correale P, Schlom J, Tsang KY.
    Immunol Lett; 1995 May 15; 47(1-2):15-24. PubMed ID: 8537095
    [Abstract] [Full Text] [Related]

  • 3. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays.
    Munn DH, Cheung NK.
    J Exp Med; 1989 Aug 01; 170(2):511-26. PubMed ID: 2526848
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human macrophage colony-stimulating factor in nonhuman primates: selective expansion of a CD16+ monocyte subset with phenotypic similarity to primate natural killer cells.
    Munn DH, Bree AG, Beall AC, Kaviani MD, Sabio H, Schaub RG, Alpaugh RK, Weiner LM, Goldman SJ.
    Blood; 1996 Aug 15; 88(4):1215-24. PubMed ID: 8695839
    [Abstract] [Full Text] [Related]

  • 5. Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
    Schmid I, Baldwin GC, Jacobs EL, Isacescu V, Neagos N, Giorgi JV, Glaspy JA.
    Cytometry; 1995 Jun 15; 22(2):103-10. PubMed ID: 7587740
    [Abstract] [Full Text] [Related]

  • 6. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.
    Kushner BH, Cheung NK.
    Blood; 1989 May 15; 73(7):1936-41. PubMed ID: 2653466
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity.
    Young DA, Lowe LD, Clark SC.
    J Immunol; 1990 Jul 15; 145(2):607-15. PubMed ID: 2142182
    [Abstract] [Full Text] [Related]

  • 8. Macrophage colony-stimulating factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxicity.
    Mufson RA, Aghajanian J, Wong G, Woodhouse C, Morgan AC.
    Cell Immunol; 1989 Mar 15; 119(1):182-92. PubMed ID: 2646026
    [Abstract] [Full Text] [Related]

  • 9. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.
    Baldwin GC, Chung GY, Kaslander C, Esmail T, Reisfeld RA, Golde DW.
    Br J Haematol; 1993 Apr 15; 83(4):545-53. PubMed ID: 7686031
    [Abstract] [Full Text] [Related]

  • 10. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients.
    Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK.
    Blood; 1989 Feb 15; 73(3):643-6. PubMed ID: 2465038
    [Abstract] [Full Text] [Related]

  • 11. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration.
    Kleinerman ES, Knowles RD, Lachman LB, Gutterman JU.
    Cancer Res; 1988 May 01; 48(9):2604-9. PubMed ID: 3128401
    [Abstract] [Full Text] [Related]

  • 12. Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels.
    Stoudemire JB, Garnick MB.
    Blood; 1991 Feb 15; 77(4):750-5. PubMed ID: 1993217
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
    Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim HI, Levin RD, Pogrebniak HW.
    J Natl Cancer Inst; 1994 Jan 05; 86(1):39-45. PubMed ID: 8271281
    [Abstract] [Full Text] [Related]

  • 14. Recombinant human macrophage colony-stimulating factor reduces plasma cholesterol and carrageenan granuloma foam cell formation in Watanabe heritable hyperlipidemic rabbits.
    Schaub RG, Bree MP, Hayes LL, Rudd MA, Rabbani L, Loscalzo J, Clinton SK.
    Arterioscler Thromb; 1994 Jan 05; 14(1):70-6. PubMed ID: 8274480
    [Abstract] [Full Text] [Related]

  • 15. Macrophage colony-stimulating factor is required for human monocyte survival and acts as a cofactor for their terminal differentiation to macrophages in vitro.
    Brugger W, Kreutz M, Andreesen R.
    J Leukoc Biol; 1991 May 05; 49(5):483-8. PubMed ID: 2016569
    [Abstract] [Full Text] [Related]

  • 16. In vivo hematologic effects of recombinant human macrophage colony-stimulating factor.
    Ulich TR, del Castillo J, Watson LR, Yin SM, Garnick MB.
    Blood; 1990 Feb 15; 75(4):846-50. PubMed ID: 2405921
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.